Abstract：OBJECTIVE: To study the correlation between the blood serum brain natriuretic peptide (BNP) level and the left cardiac function in children with congenital heart disease (CHD). METHODS: The clinical data of 41 CHD children were retrospectively analyzed. Patients were divided into two groups based on the existence of congestive heart failure (CHF): CHD+CHF (n=21) and CHD alone (n=20). The blood serum BNP level was determined using chemiluminescence immunoassay, and the left ventricular ejection fraction (LVEF) was measured with echocardiogram. RESULTS: The serum BNP level was 1353 pg/mL (range: 926-2978) in the CHD+CHF group, which was significantly higher than in the CHD alone group［149 pg/mL (range: 75-242)］(P<0.01). The LVEF was 60% (range: 53%-65%) in the CHD+CHF group, which was significantly lower than in the CHD alone group［68% (range: 64%-72%)］(P<0.01). The serum BNP level showed a negative correlation with the LVEF level (r=-0.652, P<0.01). CONCLUSIONS: The blood serum BNP level is related to the cardiac function. For children with severe CHD+CHF, serum BNP level can be used as a sensitive indicator for evaluating cardiac function damage.
ZHANG He,LI Jiu-Jun. Correlation between the blood serum BNP level and the left cardiac function in children with congenital heart disease[J]. CJCP, 2012, 14(1): 42-44.
［1］Goto T, Takase H, Toriyama T, Sugiura T, Sato K, Ueda R, et al. Circulating concentrations of cardiac proteins indicate the severity of congestive heart failure［J］. Heart, 2003, 89(11): 1303-1307.
［2］Mangat J, Carter C, Riley G, Foo Y, Burch M. The clinical utility of brain natriuretic peptide in paediatric left ventricular failure［J］. Eur J Heart Fail, 2009, 11(1): 48-52.
［3］Blankenberg S, McQueen MJ, Smieja M, Pogue J, Balion C, Lonn E, et al. Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation(HOPE) Study［J］. Circulation, 2006, 114(3): 201-208.
［5］Ruskoaho H. Cardiac hormones as diagnostic tools in heart failure［J］. Endocr Rev, 2003, 24(3): 341-356.
［6］Hama N, Itoh H, Shirakami G, Nakagawa O, Suga S, Ogawa Y, et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction［J］.Circulation, 1995, 92(6): 1558-1564.
［7］Liang F, Gardner DG. Mechanical strain activates BNP gene transcription through a p38/NF-kappaB-dependent mechanism［J］. J Clin Invest, 1999, 104(11): 1603-1612.
［8］Lim P, Monin JL, Monchi M, Garot J, Pasquet A, Hittinger L, et al. Predictors of outcome in patients with severe aortic stenosis and normal left ventricular function: role of B-type natriuretic peptide［J］. Eur Heart J, 2004, 25 (22): 2048-2053.
［9］Braunwald E 主编,陈灏珠主译.心脏病学［M］.第5版.北京：人民卫生出版社,1999:363-368.
［11］Felker GM, Petersen JW, Mark DB. Natriuretic peptides in the diagnosis and management of heart failure［J］. CMAJ, 2006, 175 (6): 611-617.
［12］Berdagué P, Caffin PY, Barazer I, Vergnes C, Sedighian S, Letrillard S, et al. Use of N-terminal prohormone brain natriuretic peptide assay for etiologic diagnosis of acute dyspnea in elderly patients［J］.Am Heart J, 2006, 151(3): 690-698.
［13］Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, et al. Brain natriurefic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dualnatriuretic peptide system, atrial natriuretic peptide and brain natrluretic peptide［J］. J Clin Invest, 1991, 87(4): 1402-1412.
［14］Cheng V, Kazanagra R, Garcia A, Lenert L, Krishnaswamy P, Gardetto N, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study［J］. J Am Coll Cardiol, 2001, 37 (2): 386-391.
［15］Kunii Y, Kamada M, Ohtsuki S, Araki T, Kataoka K, Kageyama M, et al. Plasma brain natriuretic peptide and the evaluation of volume overload in infants and children with congenital heart disease［J］.Acta Med Okayama, 2003, 57(4): 191-197.
